Updates

“Dose of Reality” Breaking Down the Big Pharma Dollar

May 18, 2019

Part IV:  Big Pharma’s Tax Conundrum The average American spends $1 Read More

“Dose of Reality” Breaking Down the Big Pharma Dollar

May 17, 2019

Part III:  As Prices Rise, So Too Does Ad Spending The average American Read More

CSRxP: House Passage of Bipartisan CREATES Act a Pivotal Moment for Patients

May 16, 2019

Applauds Lawmakers for Advancing Market-Based Solutions to Lower Drug Prices Read More

“Dose of Reality” Breaking Down the Big Pharma Dollar

May 16, 2019

Part II: An Industry Booming Off of Price-Gouging The average American spends Read More

CSRxP Encourages U.S. House of Representatives to Pass Bipartisan CREATES Act

May 16, 2019

Commends Lawmakers of Both Parties for Working Together to Advance Key Drug Read More

“Dose of Reality” Breaking Down the Big Pharma Dollar

May 15, 2019

Part I: The Math Undercuts the R&D Defense The average American spends Read More

CSRxP Applauds Bipartisan Bill To Strengthen Drug Pricing Transparency

May 14, 2019

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) today Read More

CSRxP Study Confirms: Big Pharma Invests Boldly in Profits and Advertising — Not R&D

May 14, 2019

Analysis Finds Industry Spending on Advertising, Overhead and Profits More Read More

CSRxP Praises FDA For Finalizing Guidance On Interchangeable Biologics

May 10, 2019

Clearer Guidelines Will Increase Choice and Help Lower Prices Washington Read More

THEY SAID IT! House Energy & Commerce Lawmakers Roast Big Pharma, Pledge Bipartisan Action and Question the Rebate Rule

May 10, 2019

Washington, D.C. – The House Energy & Commerce Subcommittee on Health Read More

CSRxP: Congress Takes First Step On Drug Pricing, Now Lawmakers Must Deliver

May 8, 2019

Encourages House Leaders To Keep The Momentum Going Following Passage Of First Read More

CSRxP Urges House Lawmakers to Pass First Drug Pricing Bills of the Year

May 8, 2019

Vote On Orange And Purple Book Bills Should Mark Beginning Of A Series Of Read More